share_log

藥明康德：海外監管公告

WUXI APPTEC: Overseas Regulatory Notice

HKEX ·  Jul 29 08:19

Summary by Moomoo AI

WUXI APPTEC專注於合成藥物、電腦軟件、數據庫以及相關的組合化學和製藥諮詢服務的製造、加工、開發和研究。截至2024年6月30日，公司現金及現金等價物總額為146.7億元人民幣，衍生金融資產從4.14億元人民幣減至零，應收賬款為78.9億元人民幣，並提供了27.77億元人民幣的壞賬準備。存貨為52.3億元人民幣，存貨跌價準備為1.3469億元人民幣。長期股權投資總額為280.9億元人民幣，主要投資於WuXi XDC Cayman Inc.和WuXi Healthcare Ventures II, L.P.固定資產為176.2億元人民幣，其中包括泰興新藥研發中心和生產基地項目第一階段。無...展開全部
WUXI APPTEC專注於合成藥物、電腦軟件、數據庫以及相關的組合化學和製藥諮詢服務的製造、加工、開發和研究。截至2024年6月30日，公司現金及現金等價物總額為146.7億元人民幣，衍生金融資產從4.14億元人民幣減至零，應收賬款為78.9億元人民幣，並提供了27.77億元人民幣的壞賬準備。存貨為52.3億元人民幣，存貨跌價準備為1.3469億元人民幣。長期股權投資總額為280.9億元人民幣，主要投資於WuXi XDC Cayman Inc.和WuXi Healthcare Ventures II, L.P.固定資產為176.2億元人民幣，其中包括泰興新藥研發中心和生產基地項目第一階段。無形資產報告為18.2億元人民幣，商譽為18.4億元人民幣，主要來自XenoBiotic Laboratories, Inc.和WuXi AppTec, Inc.公司收入來自WuXi Chemistry、WuXi Testing、WuXi Biology、WuXi ATU和國內新藥研發服務(WuXi DDSU)等業務部門。公司享有高新技術企業和先進技術服務企業的優惠稅率，多家子公司稅率降至15%。公司收到與資產獲取相關的政府補助，作為遞延收入確認並根據相關資產的使用壽命攤銷。公司確認了23.2億元人民幣的使用權資產和非短期及非低價值資產租賃的租賃負債。WUXI APPTEC從事現金流量避險活動，先前報告的衍生金融工具為4.14億元人民幣，現已降至零。公司持有多家子公司和合資企業的投資，在報告期間投資發生重大變化。WUXI APPTEC報告2024年上半年淨利潤為42.8億元人民幣，綜合收入總額為43億元人民幣。公司的實際控制人為李革博士、張兆輝先生和劉曉忠先生。公司運營假設為持續經營，沒有顯示可能影響其持續經營能力的重大變化跡象。
WUXI APPTEC focuses on the manufacturing, processing, development, and research of synthetic drugs, computer software, databases, and related combinatorial chemistry and pharmaceutical consulting services. As of June 30, 2024, the company's total cash and cash equivalents were RMB 14.67 billion, derivative financial assets decreased from RMB 0.414 billion to zero, accounts receivable were RMB 7.89 billion, and a bad debt provision of RMB 2.777 billion was provided. Inventory was RMB 5.23 billion, and inventory depreciation provision was RMB 0.13469 billion. Long-term equity investment totaled RMB 28.09 billion, mainly invested in WuXi XDC Cayman Inc. and WuXi Healthcare Ventures II, L.P. Fixed assets were RMB 17.62 billion, including the first phase of the Taixing new drug research and development center and production base project. Intangible assets were reported...Show More
WUXI APPTEC focuses on the manufacturing, processing, development, and research of synthetic drugs, computer software, databases, and related combinatorial chemistry and pharmaceutical consulting services. As of June 30, 2024, the company's total cash and cash equivalents were RMB 14.67 billion, derivative financial assets decreased from RMB 0.414 billion to zero, accounts receivable were RMB 7.89 billion, and a bad debt provision of RMB 2.777 billion was provided. Inventory was RMB 5.23 billion, and inventory depreciation provision was RMB 0.13469 billion. Long-term equity investment totaled RMB 28.09 billion, mainly invested in WuXi XDC Cayman Inc. and WuXi Healthcare Ventures II, L.P. Fixed assets were RMB 17.62 billion, including the first phase of the Taixing new drug research and development center and production base project. Intangible assets were reported as RMB 1.82 billion, and goodwill was RMB 1.84 billion, mainly from XenoBiotic Laboratories, Inc. and WuXi AppTec, Inc. The company's revenue came from business units such as WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, and domestic new drug research and development services (WuXi DDSU). The company enjoys preferential tax rates for high-tech enterprises and advanced technology service enterprises, and the tax rates of many subsidiaries have been reduced to 15%. The company has received government grants related to asset acquisition, recognized as deferred income, and amortized according to the useful life of the relevant assets. The company has confirmed the right-of-use assets and lease liabilities of non-short-term and non-low-value lease liabilities of RMB 2.32 billion. WUXI APPTEC engages in cash flow hedging activities, and the previously reported derivative financial instruments were RMB 0.414 billion, which has now decreased to zero. The company holds investments in multiple subsidiaries and joint ventures, and significant changes in investment occurred during the reporting period. WUXI APPTEC reported a net profit of RMB 4.28 billion for the first half of 2024, with a total comprehensive income of RMB 4.3 billion. The actual controllers of the company are Dr. Li Ge, Mr. Zhang Zhaohui, and Mr. Liu Xiaozhong. The company's operating assumption is continued operation, and no significant changes that may affect its ability to continue operations have been shown.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated